10x Genomics is kicking off the year with a $35 million extension to its series D round. This brings the Pleasanton, CA-based company’s total financing to date to $243 million. Meritech Capital led the round and Fidelity along with Wells Fargo participated.
As a company, we’ve seen tremendous growth and expansion in the last year,” Serge Saxonov, CEO and co-founder of 10x Genomics, said in a release. “We’ve released new products, announced new facilities, and welcomed two incredible companies to the 10x team. Today’s funding announcement will allow us to continue with this momentum into 2019 as we scale 10x to become a company that impacts billions of lives around the world.”
The financing round comes during a time when 10x Genomics has been busy on the M&A front. In September, the company announced it would acquire Epinomics, a specialist in the Epigenetics market, for an undisclosed sum. Just last month, 10X Genomics acquired Spatial Transcriptomics, a company focused on the emerging field of special genomics.
The company said it has also added a research facility in Sweden to develop new technologies. On the product front, 10x recently launched the Chromium Single Cell ATAC Solution and Feature Barcoding technology. The company said these two offerings will accelerate genomic research by introducing scalable multi-omics analysis.